Thymus Cancer: Staging and Treatment

Autor: Marisa Healy, BSN, RN
Contribuidor de contenido: Charles Wood, MD
Fecha de la última revisión:

What is staging for cancer?

Staging is the process of learning how much cancer is in your body and where it is. Tests like chest X-ray, CT, MRI, and a biopsy may be done to help stage your cancer. Your providers need to know about your cancer and your health so that they can plan the best treatment for you.

Staging looks at the size of the tumor and where it is, and if it has spread to other organs. The newer and more common staging system for thymus cancer is called the “TNM system,” as described by the American Joint Committee on Cancer. It has three parts:

  • T-describes the size/location/extent of the "primary" tumor in the thymus.
  • N-describes if the cancer has spread to the lymph nodes.
  • M-describes if the cancer has spread to other organs (called metastases).

Another staging system for thymus cancer, called The Masaoka staging system, is older but still sometimes used. This system stages thymus cancer based on:

  • The extent of the disease as seen on CT/MRI.
  • Spread of the tumor to nearby tissues.
  • Histologic typing (the type of cell).

Your healthcare provider will use the results of the tests you had to determine your TNM or Masaoka result and combine these to get a stage from 0 to IV.

How is thymus cancer staged?

Staging for thymus cancer is used to stage thymomas, thymic carcinomas, and neuroendocrine tumors of the thymus. Staging is based on:

  • The size of your tumor on imaging tests and what is found after surgery.
  • Any evidence of spread to other organs (metastasis).
  • Surgery to test if your lymph nodes have cancer cells. 

The staging systems are very complex. Below is a summary. Talk to your provider about the stage of your cancer. 

Stage I

  • T1A, N0, M0: The cancer has not spread into the outer layer of the thymus, OR it has grown into the nearby fatty tissues but not into the mediastinal pleura (the thin layer covering the space between the 2 lungs). It has not spread to nearby lymph nodes or to distant sites.
  • T1b, N0, M0: The cancer has grown into the nearby fatty tissue and the mediastinal pleura. It has not spread to nearby lymph nodes or distant sites.

Stage II

  • T2, N0, M0: The cancer has grown into the nearby fatty tissue and into the pericardium (the tissue sac containing the heart). It has not spread to nearby lymph nodes or distant sites.

Stage III

  • IIIA (T3, N0, M0): The cancer is growing into nearby tissues or organs, including the lungs, the vessels carrying blood into or out of the lungs, the main blood vessels taking blood away from the heart (the superior vena cava), or the phrenic nerve (the nerve that controls the diaphragm and breathing). It has not spread to nearby lymph nodes or to distant sites.
  • IIIB (T4, N0, M0): The cancer is growing into nearby tissues or organs, including the trachea (windpipe), esophagus (feeding tube), or the main blood vessels pumping blood away from the heart (T4). It has not spread to nearby lymph nodes (N0) or distant sites (M0).

Stage IV

  • IVA (Any T, N1, M0): The cancer might or might not have grown into nearby tissues or organs AND has spread to nearby lymph nodes in the front chest cavity. It has not spread to distant sites, OR
  • IVA (Any T, N0-1, M1a): The cancer might or might not have grown into nearby tissues or organs and might or might not have spread to nearby lymph nodes. The cancer has spread to the pleura (lining of the lung) or the pericardium (lining of the heart).
  • IVB (Any T, N2, M0/M1a): The cancer might or might not have grown into nearby tissues or organs AND has spread to the lymph nodes deep in the chest cavity or the neck and might or might not have spread to the pleura (lining of the lung) or the pericardium (lining of the heart), OR
  • IVB (Any T, Any N, M1b): The cancer might or might not have grown into nearby tissues or organs, might or might not have spread to nearby lymph nodes in the chest cavity or neck, but has spread to the inside of the lungs or other distant organs.

Treatment for Thymus Cancer

Treatment for thymus cancer depends on things like your stage of disease, medical history, current health, your goals for treatment, and other factors. The goal of the treatment of thymus cancer is to get rid of the cancer with few side effects. The treatments can include:

  • Surgery.
  • Radiation.
  • Chemotherapy.
  • Clinical Trials.

Surgery

Surgery is often used to treat thymus cancer. The first step is to find out whether the tumor is resectable, meaning it can be surgically removed. Removal of the whole tumor depends on whether the cancer has spread to nearby tissues or organs and on your overall health at the time of surgery.

Thymectomy is the most common surgery used in the treatment of thymus cancers. During a thymectomy, the whole thymus is removed. If the whole tumor is not resectable, your surgeon may choose to “debulk” the tumor. This means trying to remove as much of the tumor as possible. Sometimes, chemotherapy or radiation may be used before surgery to try to make the tumor smaller and easier to remove.

Radiation Therapy

Radiation is the use of high energy x-rays to kill cancer cells. Radiation can be given:

  • After surgery, to kill any cancer that was left behind. This is called adjuvant therapy and is used for nearly all stage II, III, and IV thymus cancers.
  • With chemotherapy to help the radiation therapy work better.
  • To help with symptoms caused by the cancer. This is called palliative radiation and can be used to help with shortness of breath, pain, or having a hard time swallowing.

The most common radiation used for thymus cancers is called intensity-modulated radiation therapy (IMRT), a type of external beam radiation (EBRT).

Chemotherapy

The use of chemotherapy for advanced stage tumors is more common today. Some of the most common chemotherapy medications are cisplatindoxorubicincarboplatincyclophosphamidepacilitaxelpemetrexed5-FUgemcitabine, and ifosfamide. 

Corticosteroids are non-chemotherapy medications that are sometimes used in thymus cancer treatment. Several medications are often used in combination. Two common chemotherapy combinations are: PAC (cisplatin, doxorubicin, and cyclophosphamide) or carboplatin with paclitaxel. In some cases, a medication called octreotide can be used in patients with advanced thymoma.

Some thymus cancers may be treated with targeted therapies that focus on specific gene mutations or proteins present in that tumor. Targeted therapies that may be useful in the treatment of thymus cancer are sunitinib and sorefenib.

Clinical Trials

You may be offered a clinical trial as part of your treatment plan. To find out more about current clinical trials, visit the OncoLink Clinical Trials Matching Service.

Making Treatment Decisions

Your care team will make sure you are included in choosing your treatment plan. This can be overwhelming as you may be given a few options to choose from. It feels like an emergency, but you can take a few weeks to meet with different providers and think about your options and what is best for you. This is a personal decision. Friends and family can help you talk through the options and the pros and cons of each, but they cannot make the decision for you. You need to be comfortable with your decision – this will help you move on to the next steps. If you ever have any questions or concerns, be sure to call your team.

You can learn more about thymus cancer at Oncolink.org.

Referencias

American Cancer Society, Thymus Cancer, http://www.cancer.org/cancer/thymuscancer/index

National Cancer Institute, Thymoma and Thymic Carcinoma Treatment PDQ, http://www.cancer.gov/types/thymoma/patient/thymoma-treatment-pdq

Berardi, R., Morgese, F., Garassino, M. C., & Cascinu, S. (2015). New findings on thymic epithelial tumors: Something is changing. World Journal of Clinical Oncology, 6(5), 96.

Enkner, F., Pichlhöfer, B., Zaharie, A. T., Krunic, M., Holper, T. M., Janik, S., ... & Migschitz, B. (2017). Molecular profiling of thymoma and thymic carcinoma: genetic differences and potential novel therapeutic targets. Pathology & Oncology Research23(3), 551-564.

Forquer, J. A., Rong, N., Fakiris, A. J., Loehrer, P. J., & Johnstone, P. A. (2010). Postoperative radiotherapy after surgical resection of thymoma: differing roles in localized and regional disease. International Journal of Radiation Oncology* Biology* Physics, 76(2), 440-445.

Lamarca, A., Moreno, V., & Feliu, J. (2013). Thymoma and thymic carcinoma in the target therapies era. Cancer Treatment Reviews, 39(5), 413-420.

Lemma, G. L., Lee, J. W., Aisner, S. C., Langer, C. J., Tester, W. J., Johnson, D. H., & Loehrer, P. J. (2011). Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. Journal of Clinical Oncology, 29(15), 2060-2065.

Marx, A., Ströbel, P., Schalke, B., & Weis, C. A. (2018). Pathological features of thymoma and thymic carcinoma with therapeutic implications. Mediastinum2(1)

Marx, A., & Weis, C. A. (2015). Sunitinib in thymic carcinoma: enigmas still unresolved. The Lancet Oncology16(2), 124-125.

Masaoka, A. (2010). Staging system of thymoma. Journal of Thoracic Oncology5(10), S304-S312.

Okuma, Y., Hosomi, Y., Watanabe, K., Nakahara, Y., Takagi, Y., Saito, M., & Okamura, T. (2014, May). Key components of chemotherapy for thymoma and thymic carcinoma: Anthracycline-, carboplatin-, or cisplatin-based chemotherapy. In ASCO Annual Meeting Proceedings 32(15)suppl, e185.

Shelly, S., Agmon-Levin, N., Altman, A., & Shoenfeld, Y. (2011). Thymoma and autoimmunity. Cellular and Molecular Immunology8(3), 199–202. http://doi.org/10.1038/cmi.2010.74

Ströbel, P., Hohenberger, P., & Marx, A. (2010). Thymoma and thymic carcinoma: molecular pathology and targeted therapy. Journal of Thoracic Oncology, 5(10), S286-S290.

Tagawa, T., Okamoto, T., Morodomi, Y., Iwama, E., Nakanishi, Y., Shimamatsu, S., ... & Katsura, M. (2015). P24: The predictive role of the WHO histological classification in the treatment of advanced thymoma. Journal of Thoracic Disease, 7(Suppl 3).

Thomas, A., Rajan, A., Berman, A., Tomita, Y., Brzezniak, C., Lee, M. J., ... & Guha, U. (2015). Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. The Lancet Oncology16(2), 177-186.

Toker, A., Sonett, J., Zielinski, M., Rea, F., Tomulescu, V., & Detterbeck, F. C. (2011). Standard terms, definitions, and policies for minimally invasive resection of thymoma. Journal of Thoracic Oncology, 6(7), S1739-S1742.

Venuta, F., Anile, M., Diso, D., Vitolo, D., Rendina, E. A., De Giacomo, T., ... & Coloni, G. F. (2010). Thymoma and thymic carcinoma. European Journal of Cardio-Thoracic Surgery37(1), 13-25.

Wei, M. L., Kang, D., Gu, L., Qiu, M., Zhengyin, L., & Mu, Y. (2013). Chemotherapy for thymic carcinoma and advanced thymoma in adults. Cochrane Database Syst Rev, 8.

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
A
B
C
E
F
G
H
K
L
M
N
O
P
R
S
T
U
V
 
 
Feedback?

Thank you for your feedback!